Spyre Therapeutics Q3 net loss widens to $96.12 million
Bitget2026/11/03 21:03- Spyre Therapeutics’ third-quarter 2026 net loss widened year over year to $96.12 million.
- Research and development expenses rose 97% to $89.17 million, driven by higher manufacturing costs and clinical trial expenses.
- Cash, cash equivalents and marketable securities totaled $1.07 billion at September 30; expected funding runway extends into the second half of 2029.
- SKYLINE combination-trial enrollment exceeded expectations, enabling a higher enrollment target; topline induction results remain expected in the third quarter of 2027.
- SPY072 will not advance in rheumatic diseases following insufficient benefit in rheumatoid arthritis and missed primary endpoints in two other sub-studies.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage
Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October
Crypto prices
More
